BeOne Medicines (ONC) Common Equity (2015 - 2026)
BeOne Medicines (ONC) reported Common Equity of $4.8 billion for Q1 2026, up 36.03% year-over-year from $3.5 billion in Q1 2025, and up 9.15% on a QoQ basis from $4.4 billion in Q4 2025.
BeOne Medicines (ONC) has 12 years of Common Equity data on file, last reported at $4.8 billion in Q1 2026.
- Quarterly Common Equity rose 36.03% year-over-year to $4.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 36.03% YoY) and the FY2025 annual result came in at $4.4 billion, up 30.88% from the prior year.
- Common Equity climbed to $4.8 billion in Q1 2026 per ONC's latest filing, from $4.4 billion in the prior quarter.
- Across five years, Common Equity topped out at $5.8 billion in Q1 2022 and bottomed at $3.3 billion in Q4 2024.
- The 5-year median for Common Equity is $3.8 billion (2023), against an average of $4.1 billion.
- Peak annual rise in Common Equity reached 44.22% in 2022, while the deepest fall reached 28.52% in 2022.
- Tracing ONC's Common Equity over 5 years: stood at $4.4 billion in 2022, then dropped by 19.3% to $3.5 billion in 2023, then decreased by 5.8% to $3.3 billion in 2024, then jumped by 30.88% to $4.4 billion in 2025, then rose by 9.15% to $4.8 billion in 2026.
- Per Business Quant, the three latest ONC Common Equity figures stand at $4.8 billion (Q1 2026), $4.4 billion (Q4 2025), and $4.1 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 31.42 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 13.21 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.08 Bn |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 4.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.76 Bn |
| Dec 31, 2025 | 4.36 Bn |
| Sep 30, 2025 | 4.13 Bn |
| Jun 30, 2025 | 3.77 Bn |
| Mar 31, 2025 | 3.50 Bn |
| Dec 31, 2024 | 3.33 Bn |
| Sep 30, 2024 | 3.44 Bn |
| Jun 30, 2024 | 3.37 Bn |
| Mar 31, 2024 | 3.36 Bn |
| Dec 31, 2023 | 3.54 Bn |
| Sep 30, 2023 | 3.76 Bn |
| Jun 30, 2023 | 3.80 Bn |
| Mar 31, 2023 | 4.16 Bn |
| Dec 31, 2022 | 4.38 Bn |
| Sep 30, 2022 | 4.66 Bn |
| Jun 30, 2022 | 5.20 Bn |
| Mar 31, 2022 | 5.77 Bn |
| Dec 31, 2021 | 6.13 Bn |
| Sep 30, 2021 | 3.36 Bn |
| Jun 30, 2021 | 3.61 Bn |
| Mar 31, 2021 | 4.00 Bn |
| Dec 31, 2020 | 3.87 Bn |
| Sep 30, 2020 | 4.29 Bn |
| Jun 30, 2020 | 2.55 Bn |
| Mar 31, 2020 | 2.83 Bn |
| Dec 31, 2019 | 978.36 Mn |
| Sep 30, 2019 | 1.29 Bn |
| Jun 30, 2019 | 1.57 Bn |
| Mar 31, 2019 | 1.62 Bn |
| Dec 31, 2018 | 1.75 Bn |
| Sep 30, 2018 | 1.98 Bn |
| Jun 30, 2018 | 1.23 Bn |
| Mar 31, 2018 | 1.36 Bn |
| Dec 31, 2017 | 684.23 Mn |
| Sep 30, 2017 | 764.49 Mn |
| Jun 30, 2017 | 270.17 Mn |
| Mar 31, 2017 | 308.42 Mn |
| Dec 31, 2016 | 352.91 Mn |
| Sep 30, 2016 | 187.83 Mn |
| Jun 30, 2016 | 220.05 Mn |
| Mar 31, 2016 | 243.10 Mn |
| Dec 31, 2015 | -101.77 Mn |